ASTRANA HEALTH INC (ASTH) Stock Fundamental Analysis
NASDAQ:ASTH - Nasdaq - US03763A2078 - Common Stock - Currency: USD
Overall ASTH gets a fundamental rating of 5 out of 10. We evaluated ASTH against 103 industry peers in the Health Care Providers & Services industry. ASTH has only an average score on both its financial health and profitability. ASTH is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
ASTH had positive earnings in the past year.
In the past year ASTH had a positive cash flow from operations.
ASTH had positive earnings in each of the past 5 years.
Each year in the past 5 years ASTH had a positive operating cash flow.
1.2 Ratios
With a decent Return On Assets value of 2.63%, ASTH is doing good in the industry, outperforming 61.16% of the companies in the same industry.
Looking at the Return On Equity, with a value of 4.70%, ASTH is in the better half of the industry, outperforming 60.19% of the companies in the same industry.
With a Return On Invested Capital value of 5.19%, ASTH perfoms like the industry average, outperforming 56.31% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for ASTH is below the industry average of 9.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.63% | ||
| ROE | 4.7% | ||
| ROIC | 5.19% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
1.3 Margins
With a Profit Margin value of 1.56%, ASTH perfoms like the industry average, outperforming 59.22% of the companies in the same industry.
In the last couple of years the Profit Margin of ASTH has declined.
Looking at the Operating Margin, with a value of 3.55%, ASTH is in line with its industry, outperforming 55.34% of the companies in the same industry.
In the last couple of years the Operating Margin of ASTH has declined.
The Gross Margin of ASTH (11.94%) is worse than 72.82% of its industry peers.
ASTH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.55% | ||
| PM (TTM) | 1.56% | ||
| GM | 11.94% |
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ASTH is destroying value.
ASTH has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, ASTH has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.72 indicates that ASTH is not in any danger for bankruptcy at the moment.
ASTH's Altman-Z score of 3.72 is fine compared to the rest of the industry. ASTH outperforms 69.90% of its industry peers.
ASTH has a debt to FCF ratio of 8.01. This is a slightly negative value and a sign of low solvency as ASTH would need 8.01 years to pay back of all of its debts.
The Debt to FCF ratio of ASTH (8.01) is comparable to the rest of the industry.
ASTH has a Debt/Equity ratio of 0.54. This is a neutral value indicating ASTH is somewhat dependend on debt financing.
ASTH has a Debt to Equity ratio of 0.54. This is comparable to the rest of the industry: ASTH outperforms 58.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | 8.01 | ||
| Altman-Z | 3.72 |
ROIC/WACC0.62
WACC8.33%
2.3 Liquidity
ASTH has a Current Ratio of 1.70. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
ASTH's Current ratio of 1.70 is in line compared to the rest of the industry. ASTH outperforms 58.25% of its industry peers.
A Quick Ratio of 1.70 indicates that ASTH should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.70, ASTH is doing good in the industry, outperforming 62.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.7 |
3. Growth
3.1 Past
The earnings per share for ASTH have decreased strongly by -45.45% in the last year.
ASTH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 19.19% yearly.
ASTH shows a strong growth in Revenue. In the last year, the Revenue has grown by 54.81%.
Measured over the past years, ASTH shows a very strong growth in Revenue. The Revenue has been growing by 38.01% on average per year.
EPS 1Y (TTM)-45.45%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-54.84%
Revenue 1Y (TTM)54.81%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%53.43%
3.2 Future
ASTH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.87% yearly.
The Revenue is expected to grow by 16.61% on average over the next years. This is quite good.
EPS Next Y26.29%
EPS Next 2Y33.15%
EPS Next 3Y38.2%
EPS Next 5Y31.87%
Revenue Next Year35.54%
Revenue Next 2Y28.34%
Revenue Next 3Y25.23%
Revenue Next 5Y16.61%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 35.11 indicates a quite expensive valuation of ASTH.
The rest of the industry has a similar Price/Earnings ratio as ASTH.
When comparing the Price/Earnings ratio of ASTH to the average of the S&P500 Index (27.45), we can say ASTH is valued slightly more expensively.
With a Price/Forward Earnings ratio of 16.02, ASTH is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ASTH indicates a somewhat cheap valuation: ASTH is cheaper than 72.82% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.90, ASTH is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.11 | ||
| Fwd PE | 16.02 |
4.2 Price Multiples
ASTH's Enterprise Value to EBITDA is on the same level as the industry average.
The rest of the industry has a similar Price/Free Cash Flow ratio as ASTH.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.22 | ||
| EV/EBITDA | 12.94 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ASTH's earnings are expected to grow with 38.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.34
PEG (5Y)1.83
EPS Next 2Y33.15%
EPS Next 3Y38.2%
5. Dividend
5.1 Amount
No dividends for ASTH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
25.28
+0.63 (+2.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners53.66%
Inst Owner ChangeN/A
Ins Owners9.71%
Ins Owner Change-10.17%
Market Cap1.26B
Analysts83.53
Price Target51.31 (102.97%)
Short Float %3.77%
Short Ratio5.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP26.84%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-134.77%
Min EPS beat(2)-225.16%
Max EPS beat(2)-44.39%
EPS beat(4)2
Avg EPS beat(4)-66.81%
Min EPS beat(4)-225.16%
Max EPS beat(4)1.74%
EPS beat(8)6
Avg EPS beat(8)-18.15%
EPS beat(12)9
Avg EPS beat(12)-1.53%
EPS beat(16)12
Avg EPS beat(16)7.33%
Revenue beat(2)1
Avg Revenue beat(2)1.05%
Min Revenue beat(2)-3.56%
Max Revenue beat(2)5.66%
Revenue beat(4)3
Avg Revenue beat(4)2.94%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)8.16%
Revenue beat(8)4
Avg Revenue beat(8)0.79%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.4%
PT rev (3m)-3.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.72%
EPS NY rev (1m)-10.02%
EPS NY rev (3m)-17.21%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)-2.53%
Revenue NY rev (1m)-0.65%
Revenue NY rev (3m)-0.15%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.11 | ||
| Fwd PE | 16.02 | ||
| P/S | 0.56 | ||
| P/FCF | 24.22 | ||
| P/OCF | 20.08 | ||
| P/B | 1.69 | ||
| P/tB | 5.81 | ||
| EV/EBITDA | 12.94 |
EPS(TTM)0.72
EY2.85%
EPS(NY)1.58
Fwd EY6.24%
FCF(TTM)1.04
FCFY4.13%
OCF(TTM)1.26
OCFY4.98%
SpS45.07
BVpS14.93
TBVpS4.35
PEG (NY)1.34
PEG (5Y)1.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.63% | ||
| ROE | 4.7% | ||
| ROCE | 8.23% | ||
| ROIC | 5.19% | ||
| ROICexc | 7.1% | ||
| ROICexgc | 27.85% | ||
| OM | 3.55% | ||
| PM (TTM) | 1.56% | ||
| GM | 11.94% | ||
| FCFM | 2.32% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexcg growth 3Y-13.47%
ROICexcg growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score5
Asset Turnover1.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | 8.01 | ||
| Debt/EBITDA | 3.69 | ||
| Cap/Depr | 36.16% | ||
| Cap/Sales | 0.48% | ||
| Interest Coverage | 2.55 | ||
| Cash Conversion | 57.41% | ||
| Profit Quality | 148.88% | ||
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.7 | ||
| Altman-Z | 3.72 |
F-Score5
WACC8.33%
ROIC/WACC0.62
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-45.45%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-54.84%
EPS Next Y26.29%
EPS Next 2Y33.15%
EPS Next 3Y38.2%
EPS Next 5Y31.87%
Revenue 1Y (TTM)54.81%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%53.43%
Revenue Next Year35.54%
Revenue Next 2Y28.34%
Revenue Next 3Y25.23%
Revenue Next 5Y16.61%
EBIT growth 1Y-13.63%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year83.9%
EBIT Next 3Y44.03%
EBIT Next 5Y30.85%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A